Effects of the co-administration of budesonide on the plasma exposure of cabazitaxel (Jevtana) in hormone-refractory prostate cancer patients.

Trial Profile

Effects of the co-administration of budesonide on the plasma exposure of cabazitaxel (Jevtana) in hormone-refractory prostate cancer patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Budesonide; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Dec 2015 Status changed from active, no longer recruiting to completed as per Netherlands Trial Register record.
    • 22 Apr 2012 Interim results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 22 Apr 2012 Status changed from planning to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top